Skip to content

Barjot Gill

University Health Network

2 papers in the library · 154 citations · publishing 2020

Papers

The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research.

Neuroscience and Biobehavioral Reviews November 23, 2020 H. Gill, Barjot Gill, Nelson B Rodrigues et al. 92 citations

About 40% of people with major depressive disorder have cognitive impairments, and those with treatment-resistant depression (TRD) often show such deficits. Ketamine, a rapid-acting antidepressant, may help. A systematic review of five studies found that a single low-dose intravenous infusion (0.5 mg/kg) did not worsen cognitive function. Some studies reported improvements in working memory and visual learning after ketamine treatment, while gains in processing speed and verbal learning occurred only in anxious TRD patients. The evidence suggests ketamine may have pro-cognitive effects in TRD, but more research is needed.

The emerging role of psilocybin and MDMA in the treatment of mental illness

Expert Review of Neurotherapeutics September 21, 2020 Hartej Gill, Barjot Gill, David Chen‐li et al. 62 citations

Psychedelics like psilocybin and MDMA show promise as a new type of therapy for mental health disorders. Evidence suggests they may work with just one dose, produce rapid effects, and be effective for treatment-resistant conditions, possibly serving as a standalone treatment. More clinical trials are needed to test their safety, tolerability, and effectiveness in real-world patient populations.